Revenue segments as reported by the company.

BD Medical

BD Life Sciences

BD Interventional

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling and administrative

Research and development

Acquisition-related integration and restructuring

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Becton, Dickinson and Co.

Becton, Dickinson & Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

BDX surpasses Q1 expectations, eyes growth amid market challenges

Becton, Dickinson and Co. delivered strong Q1 results, driven by the BD2025 strategy and successful product launches across segments.
While facing challenges in market dynamics and inflationary pressures, the company remains focused on margin expansion and operational efficiency.
Strategic investments, disciplined capital deployment, and a robust pipeline position BD for continued growth and performance improvement in FY 2023.

BDX reports strong Q2 performance, raises guidance for growth

Becton, Dickinson and Co. (BDX) demonstrated robust financial performance and strategic progress in Q2 2023, with raised guidance and a focus on long-term growth.
The company's strengths lie in innovation, efficiency, and sustainability initiatives, while facing challenges in operational execution and macroeconomic factors.
Opportunities for BDX include leveraging M&A for growth, capitalizing on healthcare transformation trends, and meeting long-term targets through sustained performance.
Overall, BDX's performance, strengths, challenges, and opportunities position it for continued success and resilience in the evolving healthcare landscape.

BDX reports robust Q3 earnings, focuses on Alaris system growth

BDX's Q3 earnings call highlighted strong financial performance, progress on BD2025 strategy, and strategic product launches.
The company aims to enhance operational efficiency, improve patient care, and drive revenue growth through innovative solutions.
Despite challenges like market backlog and macroeconomic factors, BD remains focused on long-term targets and margin expansion.

BD reports strong Q4 earnings, eyes growth amid challenges

BD's strong performance in Q4 and FY '23 driven by strategic initiatives and new product launches
Challenges in Q1 and macro environment expected to persist, but opportunities in new product launches and margin improvement
Focus on cash flow, margin improvement, and growth drivers to navigate challenges and drive value creation
Confidence in achieving operating margin guidance and strong performance in FY '24

Becton, Dickinson and Co. exceeds Q1 expectations, eyes growth opportunities

BD's Q1 performance was strong, with a focus on innovation and margin improvement initiatives driving robust cash flows.
Raised FY '24 guidance reflects confidence in revenue growth and margin expansion, despite potential challenges like FX moderation.
Opportunities for growth include market entry in molecular diagnostics and strategic capacity conversion in China.

BDX reports robust Q2 earnings, focuses on innovation and growth

Becton, Dickinson and Co. (BDX) delivered a strong Q2 performance, showcasing robust revenue, margin growth, and innovation. While facing challenges in market dynamics, BD remains focused on achieving its operating margin goal and capitalizing on opportunities for revenue acceleration and margin expansion.

BDX excels in Q3 with strong revenue growth and operational efficiency

Becton, Dickinson and Co. (BDX) showcased robust performance in Q3 2024, driven by organic revenue growth and operational excellence. While facing challenges in market dynamics, the company remains focused on innovation and growth strategies to achieve its financial targets and drive shareholder value.

BDX reports robust Q4 earnings, eyes growth amid market complexities

BDX delivered strong financial performance in Q4 2024, showcasing resilience and strategic focus amidst market challenges.
The company's emphasis on growth initiatives, operational excellence, and shareholder value underscores a commitment to sustainable growth.
While facing challenges such as market uncertainties and integration complexities, BD remains poised to leverage opportunities for growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

BD's (BDX) new fully-automated, high-throughput infectious disease molecular diagnostics platform in the United States to aid lab technicians in prioritizing higher value work.

BD (BDX) Introduces New Molecular Diagnostic Platform in US

BD (BDX) expands strategic partnership with Babson Diagnostics that will enable less invasive blood sample collection easier and patient-centric.

BD (BDX) Extends Partnership to Boost Diagnostic Blood Collection

510(k) Clearance of BD COR™ MX Instrument Elevates Standard of Care for Sexually Transmitted Infections FRANKLIN LAKES, N.J. , May 12, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. launch of its new, fully automated, high-throughput infectious disease molecular diagnostics platform.

BD Launches Fully Automated, High-Throughput Infectious Disease Molecular Diagnostic Platform in the U.S.

Expanded Collaboration Agreement to Make Less Invasive Blood Sample Collection More Convenient and Patient Centered AUSTIN, Texas and FRANKLIN LAKES, N.J. , May 11, 2022 /PRNewswire/ -- Babson Diagnostics, a science-first, health care technology company, and BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the expansion of a strategic partnership to move blood sample collection into new care settings, including enabling patients to collect blood samples at home for diagnostic testing.

Babson, BD Expand Strategic Partnership to Advance Diagnostic Blood Collection in New Care Settings

Align Technology

Cardinal Health

Henry Schein

McKesson

Patterson Companies

SmileDirectClub

Although Covid-19 allowed people the excuse to not see their dentist, the necessary return could benefit these dental stocks to buy. The post 7 Stock Picks to Play the Post-Pandemic Return of Dental Visits appeared first on InvestorPlace.

7 Stock Picks to Play the Post-Pandemic Return of Dental Visits

Becton, Dickinson and Company (NYSE:BDX ) Q2 2022 Earnings Conference Call May 5, 2022 8:00 AM ET Company Participants Francesca DeMartino - SVP, IR Thomas Polen - President, CEO & Chairman Christopher DelOrefice - EVP & CFO Simon Campion - EVP & President, Interventional Segment Conference Call Participants Vijay Kumar - Evercore ISI Travis Steed - Bank of America Robbie Marcus - JPMorgan Lawrence Biegelsen - Wells Fargo Securities Rick Wise - Stifel Operator Hello, and welcome to BD's Earnings Call for the Second Quarter of Fiscal 2022. At the request of BD, today's call is being recorded and will be available for replay through May 12, 2022, on BD's Investor Relations website at bd.com or by phone at 866-342-8591 for domestic calls and list the Area Code +1-203-518-9713 for international calls.

Becton, Dickinson and Company (BDX) CEO Thomas Polen on Q2 2022 Results - Earnings Call Transcript

The majority of BD's (BDX) core units witness strong revenue growth in the fiscal second quarter.

BD (BDX) Beats on Q2 Earnings and Revenues, Revises FY22 View

Becton Dickinson (BDX) delivered earnings and revenue surprises of 6.71% and 3.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Becton Dickinson (BDX) Q2 Earnings and Revenues Surpass Estimates

Revenue of $5.0 billion increased 2.1% as reported and 3.9% on currency-neutral basis Revenue driven by base revenue growth of 8.2% as reported, 10.2% currency-neutral, partially offset by decline in worldwide COVID-only testing revenues to $214 million from $474 million in the prior year GAAP diluted EPS of $1.50; adjusted diluted EPS of $3.18 Company raises mid-point of revenue and adjusted EPS guidance ranges; Adjusts for completed spin of Diabetes Care business FRANKLIN LAKES, N.J., May 5, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its second quarter of fiscal year 2022, which ended March 31, 2022.

BD REPORTS SECOND QUARTER FISCAL 2022 FINANCIAL RESULTS

Becton (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Becton (BDX) Might Surprise This Earnings Season

Scientific Advisory Board Will Review Company Innovation Pipeline and Advise on Emerging Trends in Health Care, Science and Technology FRANKLIN LAKES, N.J. , May 2, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the inaugural members of the BD Scientific Advisory Board (SAB), which is comprised of top external medical key opinion leaders, science and technology experts and experienced innovation leaders.

BD Announces Inaugural Members of Scientific Advisory Board

FRANKLIN LAKES, N.J. , April 29, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 12:00 p.m.

BD to Present at the BofA Securities 2022 Healthcare Conference

Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Becton Dickinson (BDX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Demonstrates Progress in Advancing 2030+ ESG Goals FRANKLIN LAKES, N.J. , April 26, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has been recognized by Forbes as one of the top employers in the U.S. for diversity.

BD Named to Forbes' 2022 List of Best Employers for Diversity

Developed with novel dye technology and AI guidance, new BD Horizon RealYellow™ 586 Reagents have potential to accelerate discovery and drug development in oncology, autoimmune disorders and infectious diseases FRANKLIN LAKES, N.J. , April 25, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of a new family of reagents that enables researchers to gain improved data resolution and greater insights from samples compared to traditional fluorochromes, made possible by their innovative development using novel dye technology and artificial intelligence (AI) guidance.

New BD Reagents Enable Researchers to Break Through Resolution Boundaries in Flow Cytometry

Institute will drive sustainable innovation in three areas of environmental stewardship, furthering progress toward the company's 2030+ environmental, social and governance (ESG) commitments FRANKLIN LAKES, N.J. , April 22, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the formation of the Sustainable Medical Technology Institute, a model of practice within the organization that will bring together BD researchers and engineers, as well as quality, regulatory, policy and operational expertise, to focus on reducing the environmental impact of the company's product portfolio in three areas, including adopting sustainable product design strategies, developing and deploying sustainable sterilization technologies, and addressing materials of concern (MOC).

BD Forms Sustainable Medical Technology Institute to Reduce the Environmental Impact of its Product Portfolio

We think Becton Dickinson stock is currently a better pick than Union Pacific stock, given its better prospects and comparatively lower valuation. UNP stock is trading at 7.6x trailing revenues compared to just 3.8x for BDX stock.

This Company Is Likely To Offer Better Returns Over Union Pacific Stock

Archer-Daniels-Midland Company

Aflac

Allegion

Amgen

Broadcom

Dover

Con Ed

Emerson Electric

Gilead Sciences

W.W. Grainger

Johnson & Johnson

Kraft Heinz

Kontoor Brands Inc

LyondellBasell Industries

McDonald's

Microsoft

PepsiCo

Pfizer

Southern Company

T. Rowe Price Group

Trane Technologies plc

Unilever

The start of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated.

Dividend Income Update March 2022

Phibro Animal Health

UnitedHealth Group

Stocks like Becton, Dickinson and Company (BDX), Phibro Animal Health (PAHC), McKesson Corporation (MCK) and UnitedHealth Group Inc (UNH) are right picks with strong fundamentals.

Bet on These 4 Low-Beta, High-Dividend MedTech Stocks for 2022

FRANKLIN LAKES, N.J. , April 7, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will report financial results for its second quarter of fiscal year 2022 on Thursday, May 5, 2022.

BD TO ANNOUNCE FINANCIAL RESULTS FOR ITS SECOND QUARTER OF FISCAL 2022

FRANKLIN LAKES, N.J. , April 1, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has completed its spinoff of Embecta Corp. (embecta) (NASDAQ: EMBC), which holds BD's former Diabetes Care business and is now one of the largest pure-play diabetes management companies in the world.

BD Announces Completion of Embecta Corp. Spinoff

FRANKLIN LAKES, N.J. , March 31, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Alberto Mas has informed the company of his intent to retire from BD, effective at the end of the company's fiscal year on Sept.

Alberto Mas Announces Intent to Retire from BD at End of Fiscal Year

FRANKLIN LAKES, N.J. , March 30, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company today announced the early results and pricing terms of Morgan Stanley & Co. LLC's ("Morgan Stanley") previously announced cash tender offers (each, an "Offer" and collectively, the "Offers") for the notes set forth below (collectively, the "Notes" and each a "series" of Notes), up to a maximum aggregate combined purchase price (including accrued and unpaid interest from the last interest payment date to, but excluding, the applicable Settlement Date (as defined in the Offer to Purchase) ("Accrued Interest") on such Notes payable in connection with such Offers) of $200,000,000.00 (the "Maximum Tender Payment").

BD Announces Early Tender Results for Cash Tender Offers by Morgan Stanley & Co. LL

Barnes & Noble Education

Chart Industries

NEW YORK , March 25, 2022 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: S&P SmallCap 600 constituent Chart Industries Inc. (NYSE: GTLS) will replace CyrusOne Inc. (NASD: CONE) in the S&P MidCap 400, and Sonos Inc. (NASD: SONO) will replace Chart Industries in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, March 30. Global Infrastructure Partners acquired CyrusOne in a deal that closed today.

Chart Industries Set to Join S&P MidCap 400; Sonos & Embecta to Join S&P SmallCap 600

FRANKLIN LAKES, N.J. , March 25, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has been named to Newsweek's inaugural list of "America's Most Trusted Companies " in the Health Care and Life Sciences category.

News for Becton, Dickinson and Co. Stock (BDX)